Answer
The most common adverse reactions to Exblifep in the Phase 3 study were increased alanine aminotransferase (ALT; 4.8%), increased aspartate aminotransferase (AST; 3.5%), diarrhoea (2.9%) and infusion-site phlebitis (1.9%).
Sources for this answer
- EXBLIFEP 2 g/0.5 g powder for concentrate for solution for infusionADVANZ Pharma · emc · SmPC §4.8 Undesirable effects · Version 1Document updated
Sources checked